Effects of mirikizumab on histologic resolution of Crohn's sisease in a randomised controlled Phase 2 trial
Clin Gastroenterol Hepatol 2024;22:1878–88. DOI 10.1002/cgh.20059
Magro et al. evaluated histologic outcomes for mirikizumab in Crohn's disease and found that early combined histologic-endoscopic response was associated with endoscopic remission after 1 year of treatment.
The study assessed biopsy specimens and histology samples from participants of the Phase 2 SERENITY trial and evaluated histologic and endoscopic endpoints and associations between 1-year outcomes and Wk12 responses.
Keywords:
